Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Samer S. AlMasri, Mazen S. Zenati, Annissa Desilva, Ibrahim Nassour, Brian A. Boone, Aatur D. Singhi, David L. Bartlett, Lance A. Liotta, Virginia Espina, Patricia Loughran, Michael T. Lotze, Alessandro Paniccia, Herbert J. Zeh III, Amer H. Zureikat, Nathan Bahary
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Abstract Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase rese
Externí odkaz:
https://doaj.org/article/22bcc880a5264081a326a90968f1c5d6
Autor:
Amer H. Zureikat, Ibrahim Nassour, David L Bartlett, Annissa Desilva, Lance A. Liotta, Aatur D. Singhi, Virginia Espina, Alessandro Paniccia, Samer AlMasri, Nathan Bahary, Brian A. Boone, Herbert J. Zeh, Patricia Loughran, Michael T. Lotze, Mazen S. Zenati
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase resection rat
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Asif Khalid, Nathan Bahary, Sharon Winters, Lauren Stitt, Adam C. Olson, Richard S. Hoehn, Adam Slivka, Kenneth K. Lee, Ritu Sarkaria, James Ohr, Caroline J. Rieser, Randal E. Brand, Steve Burton, Vikram C. Gorantla, David L. Bartlett, Kenneth E. Fasanella, Jennifer Chennat, Rohit Das, Aatur D. Singhi, Herbert J. Zeh, Anuradha Krishnamurthy, Melissa E. Hogg, John C. Rhee, Susannah G. Ellsworth, Kevin McGrath, Alessandro Paniccia, Amer H. Zureikat
Publikováno v:
Ann Surg Oncol
AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on
Autor:
Amer H. Zureikat, Daniel Barnett, Ying Huang, Mirna Kheir Gouda, Luke Wisniewski, Douglas B. Evans, Ben Staal, Chong-Feng Gao, Peter J. Allen, Dennis Plenker, Aatur D. Singhi, Randall E. Brand, Ying Liu, David A. Tuveson, Susan Tsai, Ian Beddows, Mohammed Aldakkak, Brian B. Haab, Johnathan Hall, Richard R. Drake
Publikováno v:
Clin Cancer Res
Purpose:A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We hypothesized that a glycan biomarker for PDACs called sialylated
Autor:
M.E. Hogg, Brian A. Boone, Kenneth K. Lee, Alessandro Paniccia, Nathan Bahary, Susannah G. Ellsworth, Amer H. Zureikat, Joal D. Beane, David L. Bartlett, Asmita Chopra, Michael T. Lotze, Aatur D. Singhi, Herbert J. Zeh, Adam C. Olson, Jacob C. Hodges, Steve Burton
Publikováno v:
Ann Surg Oncol
BACKGROUND. Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and
Autor:
Ankur K. Patel, Steven A. Burton, Dwight E. Heron, Adam C. Olson, Nathan Bahary, Joshua L. Rodríguez-López, Amer H. Zureikat
Publikováno v:
Advances in Radiation Oncology
Purpose There is no consensus on treatment volumes for adjuvant stereotactic body radiation therapy (SBRT) for pancreatic cancer. Herein, we report patterns of failure after pancreatic SBRT for close/positive margins, which may inform target volume d
Autor:
A. Floortje van Oosten, Michael J. Pflüger, Wenjie Huang, Elizabeth D. Thompson, Vincent P. Groot, Steven Gallinger, Sandra Fischer, Limin Xia, Neil M. Neumann, Nicholas J. Roberts, Richard A. Burkhart, Stefan Heinrich, Alina Hasanain, Claudio Luchini, Jin He, Kim-Vy Nguyen-Ngoc, Bernat Navarro-Serer, Anne Macgregor-Das, Laura D. Wood, Maria A. Trujillo, Gemma Lionheart, Andrew J. Ewald, Peter Chianchiano, Michael Goggins, Amer H. Zureikat, Christopher L. Wolfgang, Randall E. Brand, Yea Ji Jeong, Matthias M. Gaida, Cameron Dowiak, Tammy Ng, Aatur D. Singhi, Danielle Jones, Kohei Fujikura, Bo Huang, Nicola Veronese
Publikováno v:
Cancer Res
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by extensive local invasion and systemic spread. In this study, we employed a three-dimensional organoid model of human pancreatic cancer to characterize the molecular
Autor:
Mohamed A. Adam, Alessandro Paniccia, Ibrahim Nassour, Richard S. Hoehn, Sharon Winters, Amer H. Zureikat
Publikováno v:
Journal of Gastrointestinal Surgery. 25:983-990
Robotic pancreatic surgery is expanding throughout centers across the country. We investigated national trends in the use and outcomes for robotic-assisted pancreaticoduodenectomy (RPD) and distal pancreatectomy (RDP) for primary pancreatic tumors. T